Bessemer Group
YMAB

Bessemer Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Bessemer Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-180
Closed -$1K – 2757
2024
Q4 		$1K Hold
180
– – ﹤0.01% 2427
2024
Q3 		$2K Buy
+180
New +$2.28K ﹤0.01% 2300
2020
Q3 		– Sell
-25,600
Closed -$1.11M – 1698
2020
Q2 		$1.11M Buy
+25,600
New +$968K ﹤0.01% 740

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bessemer Group's YMAB Position: Q1 2025 in Review

Bessemer Group sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 180 shares — an estimated $1K sold.

Bessemer Group first reported a position in YMAB in Q2 2020 and held it in 3 quarters. The position peaked at $1.11M in Q2 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Bessemer Group reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bessemer Group sold 180 Y-mAbs Therapeutics shares in Q1 2025, an estimated $1K.
  • Bessemer Group first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 3 quarters.
  • Bessemer Group's Y-mAbs Therapeutics position peaked at $1.11M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Bessemer Group's 13F filing for Q1 2025, filed 23 Apr 2025.